scholarly journals Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot

2021 ◽  
Author(s):  
Anna Lee ◽  
Jung J. Kang ◽  
Havah Bernstein ◽  
Kathryn E. Marqueen ◽  
Brian Neal ◽  
...  
Author(s):  
A. Lee ◽  
H. Bernstein ◽  
C. Kelly ◽  
M. Dickson ◽  
C.J. Tsai ◽  
...  

2014 ◽  
Vol 75 (S 02) ◽  
Author(s):  
Annie Chan ◽  
E. Weyman ◽  
T. Goldsmith ◽  
L. Wirth ◽  
J. Clark ◽  
...  

2020 ◽  
Author(s):  
C Dumke ◽  
S Lautenschlaeger ◽  
F Eberle ◽  
G Iancu ◽  
M Thiemer ◽  
...  

2006 ◽  
Author(s):  
James McDonough ◽  
Steven Avery ◽  
Peter Bloch ◽  
Dickson Goulart ◽  
Mark Ingram ◽  
...  

2021 ◽  
Vol 19 ◽  
pp. 78-84
Author(s):  
Hyeri Lee ◽  
Jennifer Pursley ◽  
Hsiao-Ming Lu ◽  
Judith Adams ◽  
Thomas DeLaney ◽  
...  

2008 ◽  
Vol 35 (11) ◽  
pp. 4800-4807 ◽  
Author(s):  
Liyong Lin ◽  
Carlos Vargas ◽  
Wen Hsi ◽  
Daniel Indelicato ◽  
Roelf Slopsema ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Bruno Speleers ◽  
Max Schoepen ◽  
Francesca Belosi ◽  
Vincent Vakaet ◽  
Wilfried De Neve ◽  
...  

AbstractWe report on a comparative dosimetrical study between deep inspiration breath hold (DIBH) and shallow breathing (SB) in prone crawl position for photon and proton radiotherapy of whole breast (WB) and locoregional lymph node regions, including the internal mammary chain (LN_MI). We investigate the dosimetrical effects of DIBH in prone crawl position on organs-at-risk for both photon and proton plans. For each modality, we further estimate the effects of lung and heart doses on the mortality risks of different risk profiles of patients. Thirty-one patients with invasive carcinoma of the left breast and pathologically confirmed positive lymph node status were included in this study. DIBH significantly decreased dose to heart for photon and proton radiotherapy. DIBH also decreased lung doses for photons, while increased lung doses were observed using protons because the retracting heart is displaced by low-density lung tissue. For other organs-at-risk, DIBH resulted in significant dose reductions using photons while minor differences in dose deposition between DIBH and SB were observed using protons. In patients with high risks for cardiac and lung cancer mortality, average thirty-year mortality rates from radiotherapy-related cardiac injury and lung cancer were estimated at 3.12% (photon DIBH), 4.03% (photon SB), 1.80% (proton DIBH) and 1.66% (proton SB). The radiation-related mortality risk could not outweigh the ~ 8% disease-specific survival benefit of WB + LN_MI radiotherapy in any of the assessed treatments.


2016 ◽  
Vol 18 (suppl 3) ◽  
pp. iii162.2-iii162
Author(s):  
Yasmin Lassen-Ramshad ◽  
Anita Mahajan ◽  
Leif Christensen ◽  
Gorm von Oettingen ◽  
Benedicte Parm Ulhøi ◽  
...  
Keyword(s):  

Sarcoma ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-5 ◽  
Author(s):  
Sheron Latcha ◽  
Robert G. Maki ◽  
Gary K. Schwartz ◽  
Carlos D. Flombaum

Background. Pharmacokinetic data on clearance of ifosfamide in hemodialysis patients are limited. Consequently, these patients are excluded from therapy with this agent. We review the outcomes for patients at our institution with end stage renal disease on dialysis who received ifosfamide for metastatic sarcoma.Patients and Methods. We treated three patients with end stage renal disease on hemodialysis with escalating doses of ifosfamide. Data on radiographic response to therapy, WBC and platelet counts, signs or symptoms of infection, neuropathy and bladder toxicity are reported. Starting doses of ifosfamide were based on review of the literature available with subsequent modifications based on each patient's prior exposure to myelosuppressive agents and on symptoms of neurotoxicity and the degree of myelosuppression following each cycle of chemotherapy.Results. Myelosuppression was the most common side effect from therapy, but no patient developed a life threatening infection, neurotoxicity, or hematuria. One patient developed epistaxis in the setting of thrombocytopenia while on warfarin therapy. All patients had clinical evidence for therapeutic response and two had documented radiographic improvement following ifosfamide administration.Conclusion. Ifosfamide can be used safely in combination with hemodialysis in patients with end stage renal disease.


Sign in / Sign up

Export Citation Format

Share Document